XML 34 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements Of Cash Flows (USD $)
In Thousands, unless otherwise specified
 9 Months Ended
Feb. 26, 2012
Feb. 27, 2011
Cash flows from operating activities:    
Consolidated net income $ 10,205 $ 6,908
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 4,111 3,910
Stock-based compensation expense 1,314 1,398
Tax benefit from stock-based compensation expense (5,511) (2,017)
Increase in receivable from Monsanto for guaranteed termination fee   (600)
Deferred taxes 157 1,237
Change in investment in non-public company (fair market value) (4,726)  
Changes in current assets and current liabilities:    
Accounts receivable, net (1,718) (667)
Accounts receivable, related party 75 556
Income taxes receivable 5,870 2,367
Inventories, net 229 (2,827)
Issuance of notes and advances receivable (3,699) (3,068)
Collection of notes and advances receivable 3,196 3,118
Prepaid expenses and other current assets 3,577 824
Accounts payable (2,295) 731
Related party accounts payable (83) (289)
Accrued compensation 837 842
Other accrued liabilities (691) 436
Deferred revenue (2,313) (425)
Net cash provided by operating activities 8,535 12,434
Cash flows from investing activities:    
Purchases of property and equipment (3,892) (4,875)
Purchase of marketable securities (25,679) (57,602)
Proceeds from maturities of marketable securities 19,581 19,980
Proceeds from sales of marketable securities 9,128 26,287
Investment in non-public company (fair market value)   (15,000)
Net cash used in investing activities (862) (31,210)
Cash flows from financing activities:    
Repurchase of outstanding common stock (5,007) (1,184)
Taxes paid by Company for stock swaps and RSUs (38) (57)
Proceeds from the sale of common stock 91 126
Tax benefit from stock-based compensation expense 5,511 2,017
Principal payments on long-term debt (3,330) (2,940)
(Increase) decrease in other assets (244) 38
Payments to minority interest holders (257) (362)
Net cash used in financing activities (3,274) (2,362)
Net increase in cash and cash equivalents 4,399 (21,138)
Cash and cash equivalents at beginning of period 8,135 27,817
Cash and cash equivalents at end of period 12,534 6,679
Supplemental schedule of noncash operating activities:    
Income tax expense not payable 5,511 2,017
Long-term receivable from Monsanto for guaranteed termination fee   600
Unrealized loss from interest rate swap $ 65 $ 40